Skip to content
Abierto

Award notice

Clinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strains

75A50125C00008

Office of Assistant Secretary for Preparedness and Response, Aspr Administration for Strategic Preparedness and Response. Research and Development in Biotechnology (except Nanobiotechnology).

Awarded

Osivax

$98,593,151.00 on the award notice, July 25, 2025, contract 75A50125C00008

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Osivax
UEI
M4YDKJJRJYC7
CAGE
FBDR2
Vendor location
Paris 8
Contract
75A50125C00008, definitive contract
Obligated
$19,485,392.00, potential $98,593,151
Actions
3 between July 25, 2025 and May 19, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Osivax - Clinical Proof of Concept of OVX836, a Single-Shot Broadly Protective Influenza a Vaccine for Immediate Protection Against Emerging Pandemic Strains
Match
award number 75A50125C00008 equals the contract number; same sub-agency 7505 (high confidence)

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. October 14, 2025

    Award notice, originally solicitation

    Awarded to OSIVAX Paris 8 Île-de-France 75008 FRA for $98,593,151. SAM.gov, notice 1fce5ad56c2d466390a77292391a9d9d

  2. October 14, 2025

    Award notice, originally solicitation

    Office of Biomedical Advanced Research and Development Authority Broad Agency Announcement (BAA)

    Awarded to OSIVAX Paris 8 Île-de-France 75008 FRA for $98,593,151. SAM.gov, notice 3d5228ccb02f4c5d94250b1e1f794bac

  3. October 14, 2025

    Award notice, originally solicitation

    Awarded to OSIVAX Paris 8 Île-de-France 75008 FRA for $98,593,151. SAM.gov, notice d533887fa15e4e9ba22fd7470fb596ee

Points of contact